An implantable long-term glucose sensor using Integrated Device Technology’s (IDT) sensing technology has received government approval to be marketed in European Union (EU) member countries.
Maryland-based Senseonics received the CE Mark approval for its Eversense Continuous Glucose Monitoring (CGM) system, featuring an implanted glucose sensor that lasts up to 90 days, or about six times longer than non-implantable systems currently on the market.
The IDT technology incorporates an LED driver, temperature sensor, photodiodes and other components in a compact package to drive glucose measurements, which are wirelessly communicated to an on-body wearable transmitter.
In developing the semiconductor for Senseonics, IDT engineers selected a technology usually used for hearing aids that can be operated at a voltage as low as 0.85 V.
The biotech company Roche announced last month that it will market the Eversense CGM system in Italy, Germany and the Netherlands.
Senseonics Holdings, Inc. is a medical technology company that designs, develops and commercializes glucose monitoring products for diabetes patients. The company’s first generation continuous glucose monitoring system, Eversense, includes a small sensor, smart transmitter and mobile application.
Based on fluorescence sensing technology, the sensor is designed to be inserted subcutaneously and communicate with the smart transmitter to wirelessly transmit glucose levels to a mobile device. After insertion, the sensor is designed to continually and accurately measure glucose levels.
